Skip to Main Content
Table 3

ORsa for prostate cancer in relation to AIB/SRC-3 CAG/CAA and AR CAG or GGN repeat lengths in Chinese men

AR polymorphismsCAG/CAA repeat length genotypes of the AIB1/SRC-3 gene
29/29<29/29<29/<29>29/29>29/<29
n1/n2bOR95% CIn1/n2OR95% CIn1/n2OR95% CIn1/n2OR95% CIn1/n2OR95% CI
CAG repeat lengthc                
 ≥23 29/64 1.00  31/65 1.05 0.57–1.94 9/14 1.42 0.55–3.66 1/4 0.55 0.06–5.20 4/4 2.21 0.51–9.48 
 <23 37/64 1.27 0.70–2.32 50/55 2.00 1.12–3.59 19/15 2.78 1.24–6.26 8/7 2.50 0.83–7.60 1/3 0.72 0.07–7.34 
GGN repeat lengthc                
 ≥23 49/104 1.00  69/93 1.57 0.99–2.49 19/23 1.75 0.87–3.51 8/8 2.12 0.75–5.99 3/6 1.06 0.25–4.42 
 <23 16/23 1.47 0.71–3.04 12/24 1.07 0.49–2.31 7/6 2.47 0.79–7.77 1/3 0.70 0.07–6.94 2/0   
AR polymorphismsCAG/CAA repeat length genotypes of the AIB1/SRC-3 gene
29/29<29/29<29/<29>29/29>29/<29
n1/n2bOR95% CIn1/n2OR95% CIn1/n2OR95% CIn1/n2OR95% CIn1/n2OR95% CI
CAG repeat lengthc                
 ≥23 29/64 1.00  31/65 1.05 0.57–1.94 9/14 1.42 0.55–3.66 1/4 0.55 0.06–5.20 4/4 2.21 0.51–9.48 
 <23 37/64 1.27 0.70–2.32 50/55 2.00 1.12–3.59 19/15 2.78 1.24–6.26 8/7 2.50 0.83–7.60 1/3 0.72 0.07–7.34 
GGN repeat lengthc                
 ≥23 49/104 1.00  69/93 1.57 0.99–2.49 19/23 1.75 0.87–3.51 8/8 2.12 0.75–5.99 3/6 1.06 0.25–4.42 
 <23 16/23 1.47 0.71–3.04 12/24 1.07 0.49–2.31 7/6 2.47 0.79–7.77 1/3 0.70 0.07–6.94 2/0   
a

Adjusted for age.

b

n1 number of cases; n2, number of controls.

c

Median number of repeats among controls was used for the cutoff.

Close Modal

or Create an Account

Close Modal
Close Modal